Journals / Anadolu Kliniği Tıp Bilimleri Dergisi / 2017 / Cilt: 22 - Sayı: 3

Clinical Trials in Underdeveloped Countries and Ethical Violations: the Nigerian Case of a Phase III Antibiotic Trial

Az Gelişmiş Ülkelerde Klinik Araştırmalar ve Etik İhlaller: Nijerya Faz III Antibiyotik Deneyi Örneği

Pages
212–219
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The discussed scandal constitutes another historical example indicating that what is as important as the presence of a body of established ethical guidelines is the character of the moral agent who is to choose to follow or not to follow what has been recommended in these texts

📌 3 Key Takeaways

🎯
Objective & Hypothesis:X, one of the globally leading pharmaceutical companies, has been accused of having performed an illegal and unethical phase III clinical trial on Nigerian children to test its new antibiotic agent in 1996.
📊
Key Findings & Data:The present retrospective study reviewing the contemporaneous reports and documents aims to present this case that did occur as recently as the mid-1990s despite the vast body of contemporary ethicolegal regulations developed to prevent the reoccurrence of unethical clinical trials similar to those in the mid-20th century.
💡
Conclusion & Impact:The discussed scandal constitutes another historical example indicating that what is as important as the presence of a body of established ethical guidelines is the character of the moral agent who is to choose to follow or not to follow what has been recommended in these texts
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

X, one of the globally leading pharmaceutical companies, has been accused of having performed an illegal and unethical phase III clinical trial on Nigerian children to test its new antibiotic agent in 1996. The allegations reported by the international media subsequently met with intense reaction and were brought to court. The conclusion arrived at in the long-obscured investigation report ordered by the Nigerian government was that the company X conducted a clinical trial violating the Helsinki Declaration and the United Nations Convention on the Rights of the Child. Indeed, the company admitting having obtained only verbal consent made, when litigated, compensatory payments to the families of the child subjects. The present retrospective study reviewing the contemporaneous reports and documents aims to present this case that did occur as recently as the mid-1990s despite the vast body of contemporary ethicolegal regulations developed to prevent the reoccurrence of unethical clinical trials similar to those in the mid-20th century. The discussed scandal constitutes another historical example indicating that what is as important as the presence of a body of established ethical guidelines is the character of the moral agent who is to choose to follow or not to follow what has been recommended in these texts

Özet

Dünyadaki en büyük ilaç şirketlerinden biri olan X, yeni bir antibiyotik ajanı test etmek için 1996'da Nijerya'da çocuklar üzerinde kanuna ve tıp ahlakına aykırı faz III bir klinik deney gerçekleştirmiş olmakla suçlanmıştır. Uluslararası medyada yer bulan bu iddialar sonrasında şiddetli tepkilere neden olmuş ve mahkemeye taşınmıştır. Vakaya dair Nijerya hükumetince hazırlatılan inceleme raporunda varılan ve yıllarca gizli tutulan sonuç, X'in Helsinki Bildirgesi'ne ve Birleşmiş Milletler Çocuk Hakları Sözleşmesi'ne aykırı bir araştırma gerçekleştirdiği olmuştur. Nitekim yalnızca sözlü onam almış olduğunu kabul eden X, dava edilince, denek çocukların ailelerine tazminat niteliğinde ödemeler yapmıştır. Bu retrospektif çalışmada, yirminci yüzyıl ortalarındaki gayriahlaki klinik deneylerin yinelenmemesi için geliştirilmiş olan tüm çağdaş etikolegal mevzuata karşın doksanlar gibi yakın bir tarihte yine de gerçekleşmiş olan bu olay, dönemin belge, rapor ve haberleri üzerinden sunulmaktadır. Söz konusu skandal, ahlaken yol gösterici metinlerin varlığı kadar bu metinlerde yazanı yapmayı ya da yapmamayı seçecek olan ahlaki öznenin karakterinin de önemli olduğuna dair, tarihten bir başka örnek niteliğindedir

🔖

Cite This Article

TEMEL, M. K. (2022). Clinical Trials in Underdeveloped Countries and Ethical Violations: the Nigerian Case of a Phase III Antibiotic Trial. Anadolu Kliniği Tıp Bilimleri Dergisi, Cilt: 22 - Sayı: 3, 212–219. https://ajindex.com/articles/437758

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Phillips B. Nigeria’s drug trial fears. BBC News, 14.3.2001
  2. Stephens J. The body hunters: where profits and lives hang in balance. The Washington Post, 17.12.2000
  3. Ford J, Tomossy GF. Globalization and clinical trials: compensating subjects in developing countries. In: Bennet B, Tomossy GF (ed.), Globalization and Health: Challenges for Health Law and Bioethics. New York: Springer Science+Business Media; 2006:32–33
  4. US Supreme Court rejects Pfizer Nigeria lawsuit appeal. BBC News, 29.6.2010
  5. Pfizer: Nigeria drug trial victims get compensation. BBC News, 11.8.2011
  6. Loue S. Forensic epidemiology in the global context: a case study of Pfizer and the trovafloxacin trial. In: Loue S. (ed.), Forensic Epidemiology in the Global Context. New York: Springer Science+Business Media; 2013:4–8
  7. Murray S. Anger at deadly Nigerian drug trials. BBC News, 20.6.2007
  8. Wise J. Pfizer accused of testing new drug without ethical approval. BMJ. 2001;322:194
  9. Annas GJ. Worst Case Bioethics: Death, Disaster, and Public Health. Oxford: Oxford University Press; 2010:192–94
  10. Panel faults Pfizer in ‘96 clinical trial in Nigeria. The Washington Post, 7.5.2006
  11. Lenzer J. Secret report surfaces: Pfizer was at fault in Nigerian drug tests. BMJ. 2006;332:1233
  12. Sané P. Concluding words. In: ten Have HJ, Jean MS (ed.), The UNESCO Universal Declaration on Bioethics and Human Rights: Background, Principles and Application. Paris: UNESCO; 2009:349–50
  13. The Nigerian Federal Ministry of Health [Nijerya Federal Sağlık Bakanlığı]. Report of the Investigation Committee on the Clinical Trial of Trovafloxacin (Trovan) by Pfizer, Kano, 1996. Mart 2001
  14. Pfizer, Inc. Trovan, Kano State Civil Case—Statement of Defense. Erişim: www.pfizer.com/files/news/trovan_ statement_defense_summary.pdf (erişildi: 10.6.2017)
  15. Bairu M. Bioethical considerations in global clinical trials. In: Chin R, Bairu M (ed.), Global Clinical Trials: Effective Implementation and Management. Londra: Academic Press (Elsevier); 2011:22
  16. Smith D. Pfizer pays out to Nigerian families of meningitis drug trial victims. The Guardian, 12.8.2011
  17. Stephens J. Pfizer to pay $75 million to settle Trovantesting suit. The Washington Post, 31.7.2009
  18. Charrow RP. Law in the Laboratory: A Guide to the Ethics of Federally Funded Science Research. Chicago: University of Chicago Press; 2010:156
  19. Erhun WO, Babalola OO, Erhun MO. Drug regulation and control in Nigeria: the challenge of cou